GAITHERSBURG, Md., Nov. 18, 2022 /PRNewswire/ -- Novavax, Inc. (NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, ...
Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty ...
A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...
Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. American adults who haven't yet gotten vaccinated against COVID-19 should consider a new option ...
The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's (NVAX) COVID-19 vaccine this week, but that deadline has passed with no clarity on ...
Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...
Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official [claimed the shots]( ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback